Title:

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Running head:

Cost-effectiveness of PCV20 among adults in Germany

Authors:

Felicitas Kühne[1], Katharina Achtert[2], Franziska Püschner[2], Dominika Urbanski-Rini[2], Juliane Schiller[2], Ernestine Mahar[1], Josephine Friedrich[1], Mark Atwood[3], Ralf Sprenger[1], Jeffrey Vietri[4], Christof von Eiff[1], Christian Theilacker[4]

Institutions:

1 Pfizer Pharma GmbH, Berlin, Germany

2 Private Institute for Applied Health Services Research (inav), Berlin, Germany

3 Policy Analysis Inc, Boston, Massachusetts, United States of America

4 Pfizer Inc., Collegeville, Pennsylvania, United States of America

Correspondence to:

Felicitas Kühne

Pfizer Pharma GmbH

Linkstr. 10

0785 Berlin

Felicitas.Kuehne@pfizer.com

+49 (0) 160 1684602

1   Acknowledgement

The authors would like to thank Reiko Sato and Julia Schiffner-Rohe for many valuable discussions and Mark van der Linden for providing IPD data. Further, we would like to thank Ahuva Hanau for medical writing.

Funding:

The research described herein and manuscript development was supported by Pfizer Pharma GmbH and Pfizer Inc.

Disclosures:

Felicitas Kühne, Josephine Friedrich, Ralf Sprenger, Christian Theilacker, Christof von Eiff, and Jeffrey Vietri are employees of Pfizer. Ernestine Mahar was an employee of Pfizer Deutschland GmbH at the time of analysis, but not at the time of publication. All of which may hold stock or stock options. Mark Atwood is an employee of Policy Analysis Inc. (PAI), which received financial support from Pfizer for this study. Katharina Achtert, Franziska Püschner, Dominika Urbanski-Rini, and Juliane Schiller are employees of the Private Institute for Applied Health Services Research (inav), which received financial support from Pfizer for this study.

2   ABSTRACT

Objectives. Despite national recommendations for use of pneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugate vaccines (PCVs) with expanded coverage have the potential to reduce the pneumococcal disease burden among adults.

Methods. Using a Markov model, we evaluated the lifetime outcomes/costs comparing 20-valent PCV (PCV20) with standard of care (SC) vaccination for prevention of CAP and IPD among adults aged ≥60 years and at-risk adults aged 18-59 years in Germany. PCV20 also was compared with sequential vaccination with 15-valent PCV (PCV15) followed by (→) PPV23 in a scenario analysis.

Results. Use of PCV20 vs. SC would prevent 54,333 hospitalizations, 26,368 outpatient CAP cases, 10,946 disease-related deaths yield 74,694 additional life-years (LYs), while lowering total medical costs by 363.2M €. PCV20 was cost saving (i.e., dominant) versus SC. Scenario analysis results suggest that the use of PCV20 would also prevent more cases and deaths, yield more LYs, and result in lower costs than using PCV15→PPV23.

Conclusions. One dose of PCV20 among adults aged ≥60 years and adults aged 18-59 years with moderate- and high-risk conditions would substantially reduce pneumococcal disease, save lives, and be cost saving compared with SC.

3   HIGHLIGHTS

- Pneumococcal disease causes significant morbidity and mortality among adults in Germany

- New, higher valent vaccines have the potential to reduce disease burden and associated costs in vulnerable populations

- 20-valent pneumococcal conjugate vaccine was found to be cost-saving compared with current standard of care for pneumococcal disease prevention among adults in Germany

4   INTRODUCTION

Streptococcus pneumoniae is a major cause of invasive (IPD) and non-invasive diseases and associated with high rates of hospitalizations and premature death, especially among older adults. [1] Community-acquired pneumonia (CAP) is the most common manifestation with more than 250,000 hospitalizations and 200,000 outpatient visits annually among adults in Germany.[1-3] Interpretation of IPD trends in adults recorded by Germany's national reference center are difficult to interpret due to improvements in disease reporting overt time [4] However, several European countries with robust IPD surveillance systems have reported an increase in IPD incidence among older adults in the 4 years prior to the COVID-19 pandemic. [5-7]

Three vaccines have been available in Germany until recently to prevent pneumococcal disease: a 23-valent pneumococcal polysaccharide vaccine (PPV23), a 13-valent pneumococcal conjugate vaccine (PCV13), and 10-valent PCV (PCV10). [8] The national Standing Committee on Vaccination (STIKO) recommends PCVs for children aged ≤24 months, and sequentially administered PCV13 and PPV23 (PCV13→PPV23) for children and adolescents aged 2-15 years with underlying medical conditions. [8] A single dose of PPV23 is recommended for immunocompetent individuals aged ≥16 years with ≥1 chronic medical condition and for all immunocompetent adults aged ≥60 years. PCV13→PPV23 (with 6-month interval) is recommended for all adults aged ≥16 years with immunocompromising conditions. [8] According to STIKO recommendations, revaccination with PPV23 after at least 6 years may be considered for individuals aged ≥16 years who have previously received PPV23. [8]

As a result of the indirect effects of paediatric PCV vaccination, the burden of vaccine-type IPD (VT-IPD) has decreased substantially among adults reaching its limits within the last years. [7] Nevertheless, the overall burden of pneumococcal disease among adults has increased, highlighting the need for vaccines with expanded serotype coverage. [7] Next

generation PCVs have the potential to further reduce the burden of pneumococcal disease in Germany. [9]

Meanwhile, two higher-valent PCVs - a 20-valent PCV (PCV20) and a 15-valent PCV (PCV15) - that include the serotypes contained in PCV13 as well as additional epidemiologically important serotypes have been approved for use in adults by the European Medicines Agency (EMA). [10,11] PCV20 contains the serotypes in PCV15 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, 33F) plus five additional serotypes (8, 10A, 11A, 12F, 15B). [12,13] Although nineteen of the twenty serotypes in PCV20 are also present in PPV23, PCV20 is expected to provide more robust protection due to its T-cell dependent immune response, generation of immunologic memory and induction of an antigenically broader and more durable antibody response. [14,15] Here we evaluated the cost-effectiveness of PCV20 compared with the current standard of care (SC) and, alternatively, compared with PCV15→PPV23, among adults aged 18 years and older in Germany.

5   METHODS

5.1   *Model Description*

The model utilizes a probabilistic framework and a Markov-type process to depict the lifetime risk of clinical outcomes and economic costs of pneumococcal diseases (i.e., IPD, all-cause CAP) in a hypothetical population of adults in Germany (Figure 1). The model population is initially defined based on age (i.e., in one-year increments) and risk profile (i.e., low-risk (without underlying diseases), moderate-risk (at least one chronic condition), or high-risk (with primary or secondary immunodeficiency) for pneumococcal disease. Persons may transition to a higher risk group (i.e., from low-risk to moderate-risk, from moderate-risk to high-risk), but not to a lower risk group, during the modeling horizon. Persons may receive PPV23 alone, PCV13→PPV23, PCV15→PPV23, PCV20 alone, or no vaccine at model entry.

Figure 1. Cost-effectiveness model schematic

The model analyses a closed cohort that is vaccinated in year 1 with revaccination according to the vaccination strategy. Expected clinical outcomes and economic costs are projected for the model population on an annual basis, based on age, risk profile, disease/fatality risk, vaccination status, vaccine type, and time since vaccination. IPD is assumed to only include bacteremia and meningitis, and all-cause CAP is stratified by setting of care (inpatient vs. outpatient). Bacteremic CAP that could fall into both categories, IPD and CAP, is categorized as IPD. Persons vaccinated at model entry may be at lower risk of future IPD and all-cause CAP; the magnitude of vaccine-associated risk reduction depends on clinical presentation (i.e., IPD or all-cause CAP), as well as the vaccine(s) administered, proportion of IPD and all-cause CAP, respectively, assumed to be vaccine-preventable, time since

vaccination, age, and risk profile. Risk of death from IPD, all-cause CAP requiring inpatient care, and other causes (i.e., other than IPD and all-cause CAP) depends upon age and risk profile.

Expected costs of medical treatment for IPD and all-cause CAP are generated based on event rates and unit costs in relation to the setting of care (i.e., inpatient vs. outpatient), age, and risk profile. Costs of vaccination—including the vaccine and its administration—are tallied in the year(s) in which vaccination occurs. The value of morbidity- and mortality-related work productivity loss also is tallied in the model. Clinical outcomes and economic costs are projected over the specified period of interest (e.g., remaining years of life from model entry [max. 82 years]) for the alternative vaccination strategies considered, and include expected: numbers of cases of IPD and all-cause CAP (inpatient and outpatient); number of deaths due to IPD and all-cause CAP; number of life-years (unadjusted and quality-adjusted); costs of medical treatment for IPD and all-cause CAP; value of morbidity- and mortality-related work loss; and costs of vaccination. Future life-years and costs may be discounted annually, and a healthcare system or societal perspective may be employed. The model was programmed in Microsoft Excel 2016 as a macro-enabled workbook (.xlsm).

5.2   *Model Estimation*

Model parameter values were estimated primarily based on published literature; unpublished sources were employed as needed. Most model parameter values can be found in Table 1. Methods of estimation of model inputs are summarized below; more detailed descriptions are available in Supplementary Material.

Population. The model population included all adults in Germany aged ≥18 years (N = 69.4M), stratified across five age groups (18-49, 50-59, 60-64, 65-74, and 75-99 years) based on German census projections for 2022. [16] The population was allocated into low-risk (immunocompetent without chronic medical conditions), moderate-risk (immunocompetent

with ≥1 chronic medical condition), and high-risk (immunocompromised) groups based on the conditions included in STIKO pneumococcal vaccination recommendations and unpublished data generated as part of a published analysis (Supplementary Material Table 1). [8,17]

Disease Incidence. Values employed for disease incidence are summarized in Supplementary Material (Tables 4-5). Annual incidence of IPD was estimated by age and risk profile using age-specific disease rates, age-specific population distributions by risk profile, and risk-specific disease rates. [17-20] IPD rates were apportioned between bacteremia and meningitis based on hospitalization data published by the Federal Statistical Office. [21] Age- and risk-specific annual incidence of inpatient and outpatient all-cause CAP, respectively, were based on a recent study that employed 2016-2019 data and age-specific population distributions. [3,16,18]

Serotype Coverage. Values employed for serotype coverage are summarized in Supplementary Material (Tables 9-10). The proportion of IPD due to vaccine serotypes in year 1 of the modeling horizon was based on unpublished National Reference Laboratory data provided to Pfizer [Pfizer GmbH, data on file] (supplemental table 9). The proportion of all-cause CAP due to pneumococcal serotypes contained in the respective vaccines in year 1 of the modeling horizon was based on age-specific data for adults in Germany who had all-cause CAP between 2017-2018; data were collected using the Pfizer serotype specific urine antigen detection (SSUAD) assay (supplemental table 10). [22] The model assumes that PCV15 and PCV20 will be recommended for children in Germany by model years 2 and 3, respectively, herd effects for serotypes unique to PCV15 were assumed to begin in model year 3 and herd effects for serotypes unique to PCV20 were assumed to begin in model year 4 (due to later approval of PCV20 compared to PCV15 for infants). Lacking German data, changes in in the proportion of IPD and CAP due to vaccine-serotypes in adults due to indirect effects from pediatric PCV15/PCV20 vaccination were extrapolated from the reductions in IPD caused by PCV13 non-PCV7 serotypes (excluding serotype 3) observed among adults following the

introduction of pediatric PCV13 in the United States (US). Serotype replacement was assumed not to occur, thus the proportion of disease due to vaccine serotypes was re-based annually (model years 3-10) to account for the reduction in overall disease [Pfizer GmbH, data on file].

Case Fatality and Mortality Risks. Annual IPD case-fatality risks (CFRs) were estimated by age and risk profile using age-specific disease rates, age-specific population distributions by risk profile, and risk-specific disease rates (Supplementary Material Table 6). [17,18,20] Age- and risk-specific CFRs due to all-cause CAP in the inpatient settings, were based on published estimates by Deb et al and adjusted using age-specific population distributions by risk profile (Supplementary Material Table 7). [17,18] In the outpatient setting, CFRs were extracted from a published Robert-Koch-Institute analysis. [23] Age-specific all-cause German mortality was apportioned across risk groups based on assumed relative risk for mortality and age-specific risk distributions Supplementary Material Table 8). [16,17]

Effectiveness of PCVs. Effectiveness data of PCVs are shown in Supplementary Material Tables 11-13. In year 1, effectiveness of PCVs against VT-IPD and vaccine-type CAP (VT-CAP) for low- and moderate-risk persons aged ≥18 years was based on data from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). [24,25] For high-risk persons aged 18-99 years, vaccine effectiveness (VE) against VT-IPD and VT-CAP in year 1 was assumed to be 80% of values for low/moderate-risk persons of the same age. [26,27] In line with findings from CAPiTA and post-hoc analyses, initial VE-PCV against VT disease was assumed to be durable for five years [24,28], then to decline 5% annually during years 6-10, 10% annually during years 11-15, and to be zero from year 16 through the end of the modelling horizon. [25] PCVs were assumed only to provide protection against the proportion of IPD and all-cause CAP caused by vaccine serotypes.

Effectiveness of PPV23. Age- and risk-specific VE-PPV23 against VT-IPD was derived from a recent real-world effectiveness study conducted among low-, moderate-, and high-risk adults in the United Kingdom aged ≥18 years. [29] VE-PPV23 against VT-IPD was assumed

to decline linearly beyond the first year of the modelling horizon, to 76.2% of initial VE by year five and to no effectiveness by year ten. [29] Consistent with evidence from recent publications, VE-PPV23 against VT-CAP was assumed to be 0%. [30-32] Note, PPV23 was assumed only to provide protection against the proportion of IPD caused by vaccine serotypes.

Costs. Age-specific payer costs of IPD hospitalization (bacteremia and meningitis, respectively) were from a previously published cost-effectiveness analysis of pneumococcal vaccination in Germany which employed estimates based on national tariffs/diagnosis-related groups and updated to 2022 Euro using the healthcare component of the consumer price index. [33,34] Age- and risk-specific costs of all-cause CAP requiring hospitalization and outpatient care only, respectively, were derived healthcare claims data and included insurer paid amounts for all healthcare encounters that occurred within 30 days of the start of the CAP episode (i.e., date of hospital admission or date of outpatient encounter for CAP) [Pfizer GmbH, data on file]. The prices of PPV23 (33.88 €), PCV13 (72.50 €), PCV15 (76.74 €), and PCV20 (76.74 €) were based on published list prices. [35] The cost of vaccine administration was assumed to be 8.19 €. [33] All costs are reported in 2022 Euro (Supplementary Material Tables 15-16).

Utilities. General population health state utilities were the same as those employed in the aforementioned published cost-effectiveness analysis (Supplementary Material Table 14). [33] An annual utility decrement for persons who experienced IPD or CAP was applied during the year in which the event occurred (IPD or hospitalized all-cause CAP: 0.13; outpatient all-cause CAP: 0.004). [25,36]

Table 1. Base case input values*

	18-49 years			50-59 years			60-64 years			65-74 years			≥75 years		
	Low	Mod	High	Low	Mod	High	Low	Mod	High	Low	Mod	High	Low	Mod	High
No. of adults (in thousands)	24,375	6,671	1,026	8,008	4,373	923	2,793	2,364	662	3,373	3,924	1,570	2,372	4,525	2,507
Annual disease incidence (per 100,000)															
Bacteremia	0.9	2.7	8.3	3.9	11.1	34.1	5.2	15.0	45.9	4.8	13.9	42.6	7.0	20.0	61.2
Meningitis	0.1	0.3	0.8	0.2	0.5	1.6	0.3	0.7	2.2	0.1	0.3	0.8	0.1	0.4	1.1
NBP requiring inpatient care	65.8	134.3	301.2	179.3	353.3	725.2	392.9	747.0	1,600.5	657.6	1,476.6	2,903.0	984.4	2,377.3	4,511.2
NBP requiring outpatient care only	269.3	546.2	657.0	358.7	756.8	943.9	368.3	736.8	1,067.0	368.6	838.7	1,240.3	368.9	964.5	1,454.2
Annual mortality/case-fatality (per 100)															
General population	0.07	0.11	0.14	0.35	0.52	0.70	0.67	1.00	1.34	1.18	1.77	2.36	4.95	7.42	9.90
Bacteremia	8.9	7.9	10.2	13.5	12.0	15.6	12.9	11.4	14.8	14.5	12.8	16.7	25.6	22.7	29.4
Meningitis	8.9	7.9	10.2	13.5	12.0	15.6	12.9	11.4	14.8	14.5	12.8	16.7	25.6	22.7	29.4
NBP requiring inpatient care	3.9	5.9	7.5	8.9	13.4	17.1	10.8	16.2	20.7	12.2	18.3	23.5	13.7	20.6	26.3
NBP requiring outpatient care only	0.0	0.0	0.0	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Medical care costs (per case)															
Bacteremia	9,397 €	9,397 €	9,397 €	10,097 €	10,097 €	10,097 €	9,928 €	9,928 €	9,928 €	7,773 €	7,773 €	7,773 €	5,326 €	5,326 €	5,326 €
Meningitis	4,732 €	4,732 €	4,732 €	5,129 €	5,129 €	5,129 €	5,260 €	5,260 €	5,260 €	5,326 €	5,326 €	5,326 €	5,348 €	5,348 €	5,348 €
NBP requiring inpatient care	5,261 €	7,375 €	9,900 €	8,213 €	8,604 €	8,709 €	7,186 €	9,584 €	9,859 €	6,734 €	9,529 €	8,194 €	6,108 €	6,753 €	6,682 €
NBP requiring outpatient care only	361 €	563 €	1,214 €	542 €	706 €	1,233 €	535 €	745 €	1,931 €	763 €	901 €	1,949 €	1,003 €	1,227 €	1,870 €
General population utilities**	0.948	0.812	0.812	0.884	0.729	0.729	0.849	0.705	0.705	0.834	0.662	0.662	0.814	0.568	0.568
Vaccine uptake†	0.0	7.1	7.1	0.0	13.0	13.0	13.3	32.0	32.0	41.0	35.2	35.2	41.0	35.2	35.2
VE PCV vs. VT-IPD															
Year 1	81.5	81.5	65.2	80.1	80.0	63.9	76.9	76.9	61.5	75.0	75.0	60.0	75.0	75.0	60.0
Year 5	81.5	81.5	65.2	80.1	80.0	63.9	76.9	76.9	61.5	75.0	75.0	60.0	75.0	75.0	60.0
Year 10	63.1	63.1	50.5	62.0	61.9	49.5	59.5	59.5	47.6	58.0	58.0	46.4	58.0	58.0	46.4
Year 15	37.2	37.2	29.8	36.6	36.6	29.2	35.1	35.1	28.1	34.3	34.3	27.4	34.3	34.3	27.4
Year 16+	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
VE PCV vs. VT-ACP															
Year 1	55.6	55.6	44.5	53.0	52.8	42.1	47.6	47.5	38.0	45.0	45.0	36.0	45.0	45.0	36.0
Year 5	55.6	55.6	44.5	53.0	52.8	42.1	47.6	47.5	38.0	45.0	45.0	36.0	45.0	45.0	36.0
Year 10	43.0	43.0	34.4	41.0	40.8	32.6	36.8	36.8	29.4	34.8	34.8	27.9	34.8	34.8	27.9
Year 15	25.4	25.4	20.3	24.2	24.1	19.2	21.8	21.7	17.3	20.6	20.6	16.4	20.6	20.6	16.4
Year 16+	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
VE PPV23 vs. VT-IPD															
Year 1	59.1	32.8	17.1	58.6	32.5	16.9	57.6	32.0	16.6	55.8	30.9	16.0	48.2	25.7	13.1
Year 5	45.1	25.0	13.0	44.6	24.8	12.9	43.9	24.4	12.7	42.5	23.6	12.2	36.7	19.6	10.0
Year 10	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

*Base case inputs for serotype coverage and herd effects are set forth in Supplementary Material

**Utilities is applies on yearly basis/year in which event occurs

†All persons receiving sequential vaccination strategy were assumed to receive second vaccine in series if alive at start of model year 2; in standard of care, all persons receiving PPSV23 were assumed to receive second dose after 6 years

ACP: all-cause community-aquired pneumania; IPD: invasive pneumococcal disease; VE: vaccine effectiveness; VT: vaccine-type

5.3 Analyses

Base Case. Clinical outcomes and economic costs were projected over a lifetime for the model population under PCV20 and SC (i.e., age/risk-dependent use of PPV23 or PCV13→PPV23 with PPV23 revaccination). Vaccine coverage was based on published estimates of vaccine coverage for adults aged 18-59 with underlying conditions and all adults aged ≥60 years in 2020 and was assumed to be the same regardless of vaccine strategy (Supplementary Material Tables 17-18). [37] In SC, all persons who received PCV13 at model entry were assumed to receive PPV23 if alive in year 2; all persons who received a dose of PPV23 (i.e., at model entry or in year 2) as part of SC were also assumed to receive a second dose of PPV23 if alive 6 years after administration of the first dose. Future costs, life-years (LYs), and quality-adjusted LYs (QALYs) were discounted at 3.0% annually; analyses were conducted from the payer perspective (i.e., excluding patient paid amounts).

Sensitivity. Sensitivity analyses were conducted to evaluate the robustness of base case results to changes in key model parameter values, including: proportion of all-cause CAP requiring hospitalization, proportion of PPV23 revaccination (SC only), assuming no herd effects, and non-zero VE-PPV23 against VT-CAP with waning after 10 and 16 years as described by Suzuki et al. and Lawrence et al. [38,39] An analysis considering the societal perspective also was conducted. Inputs employed in sensitivity analyses are detailed in Supplementary Materials.

Scenario. A scenario analysis was conducted in which PCV20 and PCV15→PPV23 (without PPV23 revaccination) were compared; all sensitivity analyses described above were also conducted.

6   RESULTS

Use of PCV20 in lieu of SC would prevent an additional 2,801 IPD cases, 51,532 hospitalized CAP cases, 26,368 outpatient CAP cases, and 10,946 disease-related deaths (Table 1). Total medical care costs would be lower by 363.2 million € and vaccination costs would increase by 6.5 million €, resulting in a 356.7 million € reduction in total costs. With total costs lower, 74,694 additional total LYs, and 49,655 additional QALYs, PCV20 was dominant compared to SC. PCV20 remained dominant in all sensitivity analyses, including those in which PPV23 was assumed to have some effectiveness against VT-CAP (VE-PPV23 vs. VT-CAP varied depending on method of estimation and age/risk).

In the scenario analysis comparing use of PCV20 with PCV15→PPV23, PCV20 resulted in better outcomes. Use of PCV20 would prevent an additional 928 cases of IPD, 12,485 cases of CAP requiring hospitalization, 5,978 cases of CAP in the outpatient setting, and 2,776 disease-related deaths (vs. PCV15→PPV23) (Table 2). Medical care and vaccination costs would be lower by 97.0 million € and 357.0 million €, respectively, thus total costs would be lower by 454.0 million €. PCV20 would add 20,277 total LYs and 13,298 QALYs and was therefore dominant compared with PCV15→PPV23. PCV20 remained dominant (vs. PCV15→PPV23) in all sensitivity analyses.

Table 2. Clinical and economic outcomes of PCV20 vs PPV23/PCV13+PPV23 among adults ages 18-99 in Germany (N=69,466,087) -- base case

	PPV23/PCV13+PPV23	PCV20	Difference
Clinical Outcomes			
No. of Cases			
IPD	216,227	213,426	-2,801
All-Cause NBP			
Hospitalized	22,776,294	22,724,762	-51,532
Requiring Outpatient Care Only	13,088,903	13,062,535	-26,368
No. of Deaths	4,606,187	4,595,242	-10,946
Total Life-Years (discounted)	1,287,861,006	1,287,935,699	74,694
Total Quality-Adjusted Life-Years (discounted)	1,013,729,588	1,013,779,243	49,655
Economic Outcomes			
Total Costs (millions)			
Medical Care	89,989.62 €	89,626.40 €	-363.22 €
Vaccination	767.13 €	773.65 €	6.52 €
Medical Care + Vaccination	90,756.75 €	90,400.05 €	-356.70 €
Cost-Effectiveness (PCV20 vs PPV23/PCV13+PPV23))			
Cost per LY	---	---	Dominant
Cost per QALY	---	---	Dominant
B. Sensitivity analyses			

	Difference in Costs (millions)	Difference in LYs	Incremental Cost per LY
10% increase in inpatient all-cause CAP incidence	-386.3 €	81,291	Dominant
10% revaccination with PPV23 (SC only)	-110.9 €	68,871	Dominant
No herd effects	-472.7 €	98,567	Dominant
VE-PPV23 vs. VT-CAP from Suzuki et al.	-248.3 €	52,534	Dominant
VE-PPV23 vs. VT-CAP from Lawrence et al.	-291.9 €	60,599	Dominant
VE-PPV23 vs. VT-CAP from Lawrence et al. with 10-year waning	-252.9 €	52,329	Dominant
Societal perspective	-680.7 €	74,694	Dominant

Table 3. Clinical and economic outcomes of PCV20 vs PCV15+PPV23 among adults ages 18-99 in Germany **(N=69,466,087) -- scenario analysis**

	PCV15+PPV23	PCV20	Difference
Clinical Outcomes			
No. of Cases			
IPD	214,452	213,524	-928
All-Cause NBP			
Hospitalized	22,740,205	22,727,721	-12,485
Requiring Outpatient Care Only	13,061,776	13,055,798	-5,978
No. of Deaths	4,600,810	4,598,034	-2,776
Total Life-Years (discounted)	1,287,786,034	1,287,806,312	20,277
Total Quality-Adjusted Life-Years (discounted)	1,013,772,240	1,013,785,638	13,398
Economic Outcomes			
Total Costs (millions)			
Medical Care	89,824.88 €	89,727.86 €	-97.02 €
Vaccination	1,131.00 €	773.97 €	-357.03 €
Medical Care + Vaccination	90,955.88 €	90,501.83 €	-454.04 €
Cost-Effectiveness (PCV20 vs PCV15+PPV23))			
Cost per LY	---	---	Dominant
Cost per QALY	---	---	Dominant
B. Sensitivity analyses			

	Difference in Costs (millions)	Difference in LYs	Incremental Cost per LY
10% increase in inpatient all-cause CAP incidence	-461.9 €	22,045	Dominant
No herd effects	-548.4 €	39,575	Dominant
VE-PPV23 vs. VT-CAP from Suzuki et al.	-434.9 €	16,313	Dominant
VE-PPV23 vs. VT-CAP from Lawrence et al.	-441.9 €	17,609	Dominant
VE-PPV23 vs. VT-CAP from Lawrence et al. with 10-year waning	-432.2 €	15,538	Dominant
Societal perspective	-873.0 €	20,277	Dominant

7 DISCUSSION

To the best of our knowledge, this is the first evaluation of the potential public health and economic impacts of next generation pneumococcal vaccination strategies for adults in Germany. The results of our analyses suggest that replacing SC with a single dose of PCV20 for adults aged ≥60 years without underlying diseases and adults aged 18-59 years with moderate- and high-risk conditions would reduce the burden of pneumococcal disease and pneumococcal-related deaths, thereby reducing health care costs and resource usage. Though, the costs of vaccination were also found to be slightly higher with PCV20 (vs. SC), the strategy involving PCV20 was found to be cost saving overall. Findings also suggest PCV20 would prevent more cases of disease and associated deaths and would reduce total costs compared with PCV15 followed by PPV23.

The benefits of a pneumococcal vaccination regimen involving PCV20 alone extend beyond those demonstrated by projected public health and economic outcomes. Several small studies suggest series completion is poor among adults in Germany for whom sequential vaccination (i.e., with PCV13→PPV23) is currently recommended, and similar trends have been observed in the US. [40-44] Thus, the availability of a single dose PCV20 strategy will likely improve vaccine uptake, leading to greater benefit in terms of pneumococcal disease prevention. The simplicity of a single dose strategy for pneumococcal disease prevention among adults may also reduce burden on providers, payers, and the healthcare system on the whole.

Our findings are consistent with several recently published analyses considering use of PCV20 in other settings, including England, Denmark, and the US. Mendes and colleagues and Olsen and colleagues found that PCV20 was cost saving compared with current recommendations (i.e., PPV23) in a cohort of all adults aged ≥65 years and moderate- and high-risk adults aged 18-64 years in England and Denmark, respectively. [45,46] In an analysis

conducted by the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) considering all adults aged ≥65 years and adults aged 19-64 years with chronic medical or immunocompromising conditions, a single dose of PCV20 was found to be cost saving compared with 2019 ACIP recommendations, which included age/risk dependent use of PPV23 alone or PCV13→PPV23. [47] We note that in a recent analysis by Smith et al., PCV20 use (vs. 2019 ACIP recommendations) among elderly US adults was found to cost $172,491 per QALY, however, differences in findings (compared with aforementioned US CDC analysis) are believed to be due, at least in part, to variation in model populations (e.g., Smith et al. excluded immunocompromised patients) as well as key parameter values (e.g., rates of pneumonia were assumed by Smith et al. to be lower). [48]

Our analyses have several noteworthy limitations. To the extent possible, model parameter values were estimated based on German data, however, data from other high-income European countries with similar health care systems were employed where German data were unavailable. It was assumed that reductions in disease attributable to the seven new serotypes included in PCV20 (i.e., PCV20 non-PCV13 serotypes) among adults via pediatric use of next generation vaccines higher-valent PCVs would be similar to reductions observed in PCV13 non-PCV7 type disease among adults following the introduction of pediatric PCV13 and that serotype replacement would not occur; however, the extent to which the magnitude and patterns of vaccine-type disease reduction may vary and whether replacement will occur is unknown. Moreover, although regulatory approval and subsequent recommendations for use of next generation PCVs among pediatrics is anticipated within the next several years, it is not guaranteed.

We did not model serotype replacement, explicitly. Though, data on the occurrence of serotype replacement exists, data on the magnitude is scarce. Further, it is unknown to what

extent replacement of serotypes newly covered by PCV15 and PCV20 will take place. Model simulations suggest that replacement may be less for high-valency PCVs. [49,50]

Another area of uncertainty surrounds vaccine effectiveness. Next generation PCVs have been licensed in Europe based on studies demonstrating immunogenicity comparable to the 13 shared serotypes in PCV13 and the remaining seven shared serotypes in PPV23. [12,51-53] Effectiveness of PCV20 and PCV15, respectively, against VT-IPD and VT-CAP was therefore assumed to be the same as VE-PCV13 against VT disease from CAPiTA. [24] While it is anticipated that the additional serotypes in higher-valent PCVs will perform similarly to PCV13 in terms of disease prevention, it is possible that the effectiveness of PCV20 and/or PCV15 may vary somewhat from PCV13. The effectiveness of PPV23 against VT-IPD was assumed to decline linearly. This was based on Djennard and colleagues and reflects the well-recognized point that conjugate vaccines elicit a T-cell dependent immune response resulting in a more robust immune reaction than the plain polysaccharide vaccine. [29] We also note that the findings presented herein likely underestimate the impact of PCV20 use among adults in Germany because multiple studies evaluating the impact of PCV13 against all-cause CAP have reported larger reductions than what would be expected if accounting only for etiologically confirmed vaccine-type pneumonia. [54-56]

Some recently published real-world data analyses suggest that PPV23 may provide limited protection against VT-CAP, but because there is considerable inconsistency across studies, we do not believe these data are sufficiently robust to employ in base case analyses. [30,32,38,39,57] Nonetheless, we conducted scenario analyses that assumed moderate PPV23 effectiveness against VT-CAP based on findings from Lawrence et al. and Suzuki et al., respectively. [38,39] Under these assumptions, SC and PCV15→PPV23 prevented more cases of all-cause CAP and associated deaths (compared with base case analyses), but PCV20

remained dominant against both strategies in all analyses conducted, with cost savings ranging from 248-292 million € (vs. SC) and from 432-442 million € (vs. PCV15→PPV23).

Current STIKO recommendations include revaccination with PPV23 on a case-by-case basis only, however, estimates of the proportion of adults who are revaccinated are not available. We therefore assumed in base case analyses that all persons in the SC strategy who received PPV23 alone or PCV13→PPV23 at model entry received a second dose of PPV23 (i.e., revaccination) 6 years later. Because this likely overestimates the cost—and associated benefits—of vaccination in the SC strategy, we conducted a sensitivity analysis in which only 10% of persons were revaccinated. With lower rates of revaccination, the costs of vaccination in SC dropped dramatically (nearly 50% compared with base case). Nonetheless, total costs with PCV20 were only slightly higher compared with SC resulting in an ICER of 985 €/LY.

We used case fatality rates from a recently published article on the burden of pneumococcal disease. [18] The mortality rates of CAP estimated in that paper were higher than previous estimates (2015) [Pfizer GmbH, data on file], so we tested the impact of more recent higher case fatality in sensitivity analyses using the previously estimated (i.e., lower) rates. Though, slightly fewer life years were saved with almost stable costs in the PCV20 strategy compared to standard of care, the PCV20 strategy was still the dominating strategy, meaning it saved more life-years while costing less than the standard of care strategy. The comparison of PCV20 to PCV15→PPV23 showed the same results in the sensitivity analysis.

The analyses presented herein were conducted from the payer perspective which does not reflect the true costs of medical care, such as patient paid amounts. Finally, our model, like all such health economic models, simplifies reality. For example, long-term consequences of pneumococcal disease—including exacerbations of underlying conditions such as COPD or asthma—also were not considered, despite evidence that such sequelae are common and costly. [58-62]

8   CONCLUSIONS

Use of a single dose of PCV20 among adults aged ≥60 years and adults aged 18-59 years with moderate- and high-risk conditions would reduce the burden of pneumococcal diseases, save more lives, and would be cost saving compared with SC. PCV20 alone would also be cost saving compared with use of PCV15→PPV23. Future research examining the real-world impact of PCV20 use on pneumococcal disease burden in Germany should aim to capture other potential benefits of a single dose vaccination strategy for pneumococcal disease prevention among adults.

9   REFERENCES

1. Pletz MW, Bahrs C. [Pneumococcal vaccination]. *Internist (Berl)*, 62(8), 807-815 (2021).
2. Ambulant erworbene Pneumonie: Bundesauswertung zum Erfassungsjahr 2019. (Ed.^(Eds) (IQTIG–Institut für Qualitätssicherung und Transparenz im Gesundheitswesen B, 2020)
3. Theilacker C, Sprenger R, Leverkus F *et al.* Population-based incidence and mortality of community-acquired pneumonia in Germany. *PLOS ONE*, 16(6), e0253118 (2021).
4. Robert Koch Institut. SurvStat@RKI 2.0 Web-basierte Abfrage der Meldedaten gemäß Infektionsschutzgesetz (IfSG) 2021. (Ed.^(Eds) (Rober Koch Institut, 2021)
5. Hanquet G, Krizova P, Dalby T *et al.* Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. *Emerg Infect Dis*, 28(1), 137-138 (2022).
6. Ladhani SN, Collins S, Djennad A *et al.* Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. *The Lancet Infectious Diseases*, 18(4), 441-451 (2018).
7. van der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. *PLoS One*, 14(8), e0220453 (2019).
8. Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2021. (34), 3--63 (2021).
9. Hurley D, Griffin C, Young M *et al.* Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. *Clin Infect Dis*, 73(7), e1489-e1497 (2021).
10. European Medicines Agency. Vaxneuvance: pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed). (Ed.^(Eds) (2021)
11. European Medicines Agency. Apexxnar Product Infomation. (Ed.^(Eds) (2022)
12. Merck & Co. Inc. Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes. (Ed.^(Eds) (2021)
13. Pfizer Inc. U.S. FDA approves PREVNAR 20™, Pfizer's pneumococcal 20-valent conjugate vaccine for adults ages 18 years or older (Ed.^(Eds) (Pfizer Inc., 2021)
14. Clutterbuck EA, Lazarus R, Yu L-M *et al.* Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells. *The Journal of Infectious Diseases*, 205(9), 1408-1416 (2012).
15. Davies LRL, Cizmeci D, Guo W *et al.* Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses. *Sci Transl Med*, 14(656), eabm4065 (2022).
16. Statistisches Bundesamt (Destatis). Population: Germany Reporting date, age years. (Ed.^(Eds) (2022)
17. Pelton SI, Shea KM, Farkouh RA *et al.* Rates of pneumonia among children and adults with chronic medical conditions in Germany. *BMC Infectious Diseases*, 15(1), 470 (2015).
18. Deb A, Podmore B, Barnett R *et al.* Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany. *Epidemiol Infect*, 150, e204 (2022).
19. Reinert RR, Haupts S, van der Linden M *et al.* Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. *Clin Microbiol Infect*, 11(12), 985-991 (2005).
20. van Hoek AJ, Andrews N, Waight PA *et al.* The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. *J Infect*, 65(1), 17-24 (2012).
21. Gesundheitsberichterstattung des Bundes. Bundesamt, S (Ed.^(Eds) (2021)
22. Bahrs C, Kesselmeier M, Kolditz M *et al.* Pneumococcal serotype distribution in adults with community-acquired pneumonia in Germany and coverage of an investigational 20-valent conjugate vaccine: a longitudinal analysis from the CAPNETZ cohort 2013-2018. In: *31st European Congress of Clinical Biology and Infectious Diseases.* (Ed.^(Eds) (Online, 2022)

23. Kuhlmann A, Treskova M, Graf von der Schulenburg J-M. Pneumokokkenerkrankungen bei Erwachsenen: Gesundheitsökonomische Evaluation unterschiedlicher Impfszenarien in Deutschland. (Ed.^(Eds) (Rober Koch Institut 2016)

24. Bonten MJM, Huijts SM, Bolkenbaas M *et al.* Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. *New England Journal of Medicine*, 372(12), 1114-1125 (2015).

25. Mangen M-JJ, Rozenbaum MH, Huijts SM *et al.* Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. *European Respiratory Journal*, 46(5), 1407-1416 (2015).

26. French N, Gordon SB, Mwalukomo T *et al.* A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. *New England Journal of Medicine*, 362(9), 812-822 (2010).

27. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. *N Engl J Med*, 349(14), 1341-1348 (2003).

28. Patterson S, Webber C, Patton M *et al.* A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). *Trials in Vaccinology*, 5, 92-96 (2016).

29. Djennad A, Ramsay ME, Pebody R *et al.* Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. *EClinicalMedicine*, 6, 42-50 (2018).

30. Chandler T, Furmanek S, Carrico R, Balcom D, Arnold F, Ramirez J. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. *Microorganisms*, 10(3), 560 (2022).

31. Dunne EM, Cilloniz C, von Mollendorf C *et al.* Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population? *Arch Bronconeumol*, (2023).

32. Heo JY, Seo YB, Choi WS *et al.* Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study. *The Journal of Infectious Diseases*, 225(5), 836-845 (2021).

33. Kuchenbecker U, Chase D, Reichert A, Schiffner-Rohe J, Atwood M. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. *PloS one*, 13(5), e0197905 (2018).

34. Statistisches Bundesamt (Destatis). Consumer Price Index: Germany Reporting date, applcation. (Ed.^(Eds) (2022)

35. LAUER-FISCHER GmbH. WEBAPO® InfoSystem. LAUER-TAXE® Kompetenz online. (Ed.^(Eds) (2023)

36. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. *Vaccine*, 22(31-32), 4203-4214 (2004).

37. Robert Koch-Institut. Impfquoten bei Erwachsenen in Deutschland, STIKO: Bestätigung der Pneumokokken-Impfempfehlung. *Epidemiologisches Bulletin*, 47 (2020).

38. Lawrence H, Pick H, Baskaran V *et al.* Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. *PLoS medicine*, 17(10), e1003326 (2020).

39. Suzuki M, Dhoubhadel BG, Ishifuji T *et al.* Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. *The Lancet infectious diseases*, 17(3), 313-321 (2017).

40. Black CL, Williams WW, Warnock R, Pilishvili T, Kim D, Kelman JA. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine

and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years. *MMWR Morb Mortal Wkly Rep*, 66(27), 728-733 (2017).

41. Morga A, Kimura T, Feng Q, Rozario N, Schwartz J. Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination. *Vaccine*, 40(15), 2274-2281 (2022).

42. Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study. *The Lancet Regional Health-Europe*, 7, 100126 (2021).

43. Sprenger R, Häckl D, Kossack N, Schiffner-Rohe J, Wohlleben J, von Eiff C. Pneumococcal vaccination rates in immunocompromised patients in Germany: A retrospective cohort study to assess sequential vaccination rates and changes over time. *PLOS ONE*, 17(3), e0265433 (2022).

44. Yang X, Zhang D, Ou W. Pneumococcal vaccination patterns among persons aged 65 years or older in the United States: A retrospective database analysis. *Vaccine*, 36(49), 7574-7579 (2018).

45. Mendes D, Averin A, Atwood M *et al.* Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England. (2021).

46. Olsen J, Schnack H, Skovdal M, Vietri J, Mikkelsen MB, Poulsen PB. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23. *J Med Econ*, 25(1), 1240-1254 (2022).

47. Leidner AJ. Summary of three economic models assessing pneumococcal vaccines in US adults. In: *ACIP Meeting.* (Ed.^(Eds) (2021)

48. Smith KJ, Wateska AR, Nowalk MP *et al.* Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors. *American Journal of Preventive Medicine*, 61(1), 28-36 (2021).

49. Croucher NJ, Løchen A, Bentley SD. Pneumococcal Vaccines: Host Interactions, Population Dynamics, and Design Principles. *Annu Rev Microbiol*, 72, 521-549 (2018).

50. Masala GL, Lipsitch M, Bottomley C, Flasche S. Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination. *J R Soc Interface*, 14(136) (2017).

51. Essink B, Sabharwal C, Cannon K *et al.* Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. *Clinical Infectious Diseases*, (2021).

52. Mohapi L, Pinedo Y, Osiyemi O *et al.* Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. *AIDS*, 36(3), 373-382 (2022).

53. Song J-Y, Chang C-J, Andrews C *et al.* Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). *Vaccine*, 39(43), 6422-6436 (2021).

54. Gessner BD, Isturiz R, Snow V, Grant LR, Theilacker C, Jodar L. The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia. *Expert Review of Vaccines*, 20(3), 269-280 (2021).

55. Hsiao A, Hansen J, Timbol J *et al.* Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine. *JAMA Network Open*, 5(3), e221111-e221111 (2022).

56. Lewnard JA, Bruxvoort KJ, Fischer H *et al.* Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults. *Clinical Infectious Diseases*, (2021).

57. Kim JH, Chun BC, Song JY *et al.* Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in

elderly population in the era of pneumococcal conjugate vaccine: A case-control study. *Vaccine*, 37(21), 2797-2804 (2019).

58. Bornheimer R, Shea KM, Sato R, Weycker D, Pelton SI. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. *PLOS ONE*, 12(10), e0184877 (2017).

59. Campling J, Jones D, Chalmers J *et al.* Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. *BMJ Open Respiratory Research*, 7(1), e000703 (2020).

60. Corrales-Medina VF, Alvarez KN, Weissfeld LA *et al.* Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease. *JAMA*, 313(3), 264-274 (2015).

61. Hughes GJ, Wright LB, Chapman KE, Wilson D, Gorton R. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. *Epidemiology and Infection*, 144(12), 2654-2669 (2016).

62. Myint PK, Hawkins KR, Clark AB *et al.* Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort. *Epidemiology and Infection*, 144(4), 803-809 (2016).